Skip to main content
Premium Trial:

Request an Annual Quote

Sylentis Concludes Phase Ia Study of Glaucoma Drug

Premium

Sylentis announced this week that it has completed a phase Ia study of its siRNA-based glaucoma drug SYL040012.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Gene Silencing News first reported in April that the trial had been concluded and that SYL040012 proved to be both safe and well tolerated (GSN 4/1/2010).

This week, Sylentis said that the 30 healthy patients in the study showed "excellent local and systemic tolerance to SYL040012, leading to very positive trial results."

The company added that it will begin a phase I/II study in patients with elevated intraocular pressure "as soon as possible."

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.